Deucrictibant

Rx-PHVS-2704PHVS/FDA decisionResearch

Pharvaris · on-demand treatment of hereditary angioedema attacksApr 23, 2027 target

Will the FDA approve Deucrictibant for on-demand treatment of hereditary angioedema attacks?

Drug profile Company Event Small moleculeNCT06343779

Primary source

YPHVS

PHVS-YES/ USDC

Outcome claim / Research candidate

NOT LISTED

Executable price

—

Change across observed prices in this window

Implied YES probability—Price-based, not a clinical forecast

Market not listed

No market price yet.

This program has no funded pool or observed trading history. Start with the evidence, or explore a clearly labeled scenario.

0 trading observationsNo live price feed

YES —NO —

This chart stays empty until observations exist. Research status is not an approval probability. A sandbox session creates a separate virtual price history.

Capital takes the other side

Market makers hold both outcome inventories. Buying moves the price; fees compensate capital at risk, but informed flow can exceed fee income.

No funded pool yet

Independent LP capital and reviewed market terms are required before listing.

Synthetic opening inventory in sandbox is not capital committed to this program. Outcome inventory is not the same as TVL. No yield or returns are promised.

Explore market making

Try virtual trading